Grupo para la caracterización molecular de las neoplasias hematológicas
Instituto de Investigación Sanitaria La Fe
Valencia, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Sanitaria La Fe (19)
2023
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
Disease markers, Vol. 2022, pp. 3132941
2021
-
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Annals of Hematology, Vol. 100, Núm. 6, pp. 1497-1508
-
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
PLoS ONE, Vol. 16, Núm. 9 September
-
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
Blood Cancer Journal, Vol. 11, Núm. 8
-
Polycythemia vera and essential thrombocythemia patients exhibit unique serum metabolic profiles compared to healthy individuals and secondary thrombocytosis patients
Cancers, Vol. 13, Núm. 3, pp. 1-12
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
2020
-
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Scientific Reports, Vol. 10, Núm. 1
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
2019
-
Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients
Frontiers in Pharmacology, Vol. 10
-
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535
2018
-
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
British Journal of Haematology
-
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia
Journal of Hematology and Oncology, Vol. 11, Núm. 1
-
Prognostic risk models for transplant decision-making in myelofibrosis
Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820
2017
-
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414